Volkmar Mueller, MD, Prof Dr, University Medical Center Hamburg-Eppendorf

Articles

Addressing Treatment Gaps in HER2+ MBC

December 13th 2021

Unmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.

Optimizing Therapy in HER2+ MBC Across the Globe

December 13th 2021

A global perspective on managing patients with HER2-positive metastatic breast cancer through multiple lines of therapy based on treatment advances.

Therapeutic Sequencing in HER2+ MBC

December 13th 2021

A global perspective pertaining to how to best sequence therapies used to treat HER2+ metastatic breast cancer based on treatment advances and data presented on at ESMO 2021.

ADCs Under Investigation for HER2+ MBC

December 6th 2021

Expectations as to where antibody-drug conjugates in the pipeline will fit into HER2-positive metastatic breast cancer treatment algorithms.

Updates in the Management of HER2+ MBC With Brain Metastases

December 6th 2021

Recent advances in the characterization and treatment of patients with HER2-positive metastatic breast cancer and brain metastases.

Updates to HER2CLIMB in HER2+ MBC

November 29th 2021

Breast oncologists react to updated overall survival data, progression-free survival data, and quality-of-life data from the HER2CLIMB study of tucatinib for HER2+ metastatic breast cancer, as well as consider using the drug in combination with other novel therapies.

Novel Combination Approaches for HER2+ MBC

November 29th 2021

An overview of novel combination regimens being investigated for the treatment of HER2+ metastatic breast cancer.

T-DXd for HER2+ MBC and Interstitial Lung Disease

November 22nd 2021

Recommendations for managing patients with HER2+ metastatic breast cancer who develop interstitial lung disease, an adverse event of trastuzumab deruxtecan.

Managing TRAEs Associated With Novel HER2+ MBC Therapies

November 22nd 2021

Recommendations for monitoring for and managing adverse events associated with newer therapies being sequenced into HER2+ metastatic breast cancer treatment algorithms.

Subgroup Analyses of DESTINY-Breast03 in HER2+ MBC

November 15th 2021

Subgroup analyses of the DESTINY-Breast03 study evaluating trastuzumab deruxtecan as second-line therapy in HER2-positive metastatic breast cancer.

Standard Treatment Approaches in HER2+ MBC

November 8th 2021

A global perspective regarding standards of care for treating HER2-positive metastatic breast cancer in earlier treatment settings.

Global Trends in HER2+ MBC

November 8th 2021

Breast oncologists from across the globe react to incidence rates of HER2-positive metastatic breast cancer as they relate to rates of progression to brain metastases and treatment advances.

Unanswered Questions in HER2+ Breast Cancer

April 14th 2021

Considerations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.

Approaches to Sequencing for Metastatic HER2+ BC

April 14th 2021

Volkmar Mueller, MD, shares insight on the potential sequencing of available therapeutics for patients with metastatic HER2+ breast cancer.

Clinical Implications of Tucatinib Approval in Europe 

April 14th 2021

Experts discuss the clinical implications of the approval of tucatinib in Europe, specifically for patients with active brain metastases.

Real-World Experience With Tucatinib in Germany and France

April 7th 2021

An examination of the real-world data supporting the use of tucatinib for patients with metastatic HER2+ breast cancer in Europe.

Favorable Safety Profile of Tucatinib for Metastatic HER2+ BC

April 7th 2021

Experts in breast oncology review the favorable safety profile of tucatinib for patients with metastatic HER2+ breast cancer.

European Commission Approval of Tucatinib in HER2+ BC

April 7th 2021

Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.